KLI
GILD icon

Kelman-Lazarov Inc’s Gilead Sciences GILD Stock Holding History

Kelman-Lazarov Inc’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-7,510
Closed -$538K – 153
2016
Q4 		$538K Sell
7,510
-250
-3% -$18.6K 0.3% 76
2016
Q3 		$599K Buy
7,760
+400
+5% +$32.5K 0.34% 74
2016
Q2 		$625K Buy
7,360
+445
+6% +$39.5K 0.36% 75
2016
Q1 		$651K Buy
+6,915
New +$624K 0.38% 77

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Kelman-Lazarov Inc's GILD Position: Q1 2017 in Review

Kelman-Lazarov Inc sold out of Gilead Sciences (GILD) in Q1 2017, closing a stake of 7,510 shares — an estimated $538K sold.

Kelman-Lazarov Inc first reported a position in GILD in Q1 2016 and held it in 4 quarters. The position peaked at $651K in Q1 2016. 1,525 funds tracked by Wall St. Rank hold GILD as of Q1 2017.

  • Kelman-Lazarov Inc reported no remaining Gilead Sciences position as of Q1 2017 after selling out during the quarter.
  • Kelman-Lazarov Inc sold 7,510 Gilead Sciences shares in Q1 2017, an estimated $538K.
  • Kelman-Lazarov Inc first reported a position in Gilead Sciences in Q1 2016 and held it in 4 quarters.
  • Kelman-Lazarov Inc's Gilead Sciences position peaked at $651K in Q1 2016.
  • 1,525 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2017.

Based on Kelman-Lazarov Inc's 13F filing for Q1 2017, filed 25 Apr 2017.